diagnost tool
abaxi second largest anim health diagnost test
manufactur us market human instrument
 continu zoeti acquir abax
implic group rais pt
three week agre spin anim health busi
form new compani vet first choic abaxi zoeti morn announc
definit merger agreement zoeti acquir abaxi
enterpris valu enterpris valu purchas price repres
multipl abax rev well trail ep comparison
trade ev/rev trade view
strong outcom abax sharehold help abax meaning expand
ou better compet howev believ overcom
competit impact given market-lead posit first-mov advantag ou
diagnost deep breadth offer also view today news posit
view hold even greater scarciti valu last stand
acquisit target assum complet merger agreement abax
expect close end rais abax pt reflect offer
number agre pay premium abax may close
price equiti valu enterpris valu expect fund
acquisit combin exist cash new debt expect deal
close end
view abax clearli warm abax last month call abax
great compani scarc resourc congratul abax team view
good outcom abax last quarter abax initi mid-teen revenu target
make abax like fastest grow anim health dx compani back
new product launch flex rapid urin sediment analyz name two
take previous flag abax target sever time
specul bidder like includ mar inc henri
schein abax tabl believ even greater scarciti
valu potenti subject bid war mar inc
expect remain market leader anim diagnost year
come ltm rev vs abax expect abax/zt becom
abax takeout premium takeout premium may appear modest
outsid takeout come premium abax
trade around last year prior stock recent spike decemb
bidder think like complet acquisit abax
said peg probabl higher bid would call mar inc
bidder think could bidder think less like given
pend merger vet first choic
deal rational zoeti look leverag strong global direct sell capabl
direct sale rep countri addit distributor rep countri
strengthen sale abax product intern deal serv diversifi
zoeti portfolio away core medicin vaccin busi ad anim
diagnost segment track grow year expect fairli rapid ftc
clearanc given materi competit overlap abax
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
import inform pleas see import disclosur begin page document
hate miss sharp move higher stock tip cap abax
manag team nice job talk develop new
rapid test instead press releas januari compani
got usda approv regret upgrad stock particularli novemb
decemb howev idea abax come doubt
abax would launch compel urin sediment analyz compet
sedivu abax offer good product recent chang strategi priorit
direct salespeopl better custom servic right thing
share abax enthusiasm new product launch materi rais
estim reflect contribut new product greater invest
salesforc rais pt reflect today merger agreement
abax encourag strateg shift abax scale direct sale forc
rep last year
drive record rapid test sale abax indic last earn call saw
record y/i growth sale rapid test driven new launch
later flow rapid assay dog launch around mid-march test
heartworm lyme ehrlichia anaplasma directli compet snap
rapid test abax expect strong part due warmer weather
beat abax drove strong result rev y/i beat
y/i /street vet rev beat
medic rev miss ep
beat
guidanc wait updat guid double-digit top- bottom-
line growth ye abax expect grow revenu mid-teen versu
prior year applaud higher precis level specif guid
believ achiev given easi comp on-going lift new product
posit call assay rev grew y/i
led abax launch urin sediment analyz gener
rev abax launch i-stat alin poc
medic instrument abax expect complet hire region account
manag diagnost specialist end total
rais dividend
challeng call abax sold vetscan chemistri instrument
last year hematolog instrument last year due
manag consid distract rep focus new product
medic revenu miss gm came
slightli ahead y/i level
distributor abax note distributor feedback outstand
relationship strong despit recent lower margin
model updat abax model first time follow recent earn
call reflect expect higher sale new product new sale
peopl rais rev rev
given rise momentum vetscan sa
rais adj ep adj ep
stock price compani discuss report
hold unchang target price may
diagnost tool
canaccord genuiti estim compani report
detail financi model includ balanc sheet incom statement cash flow project avail may obtain contact canaccord genuiti sale person author analyst whose contact inform appear front page report
hold unchang target price may
diagnost tool
canaccord genuiti estim compani report
hold unchang target price may
diagnost tool
canaccord genuiti estim compani report
hold unchang target price may
diagnost tool
author analyst canaccord genuiti whose name appear front page research herebi certifi
recommend opinion express research accur reflect author analyst person independ
object view design invest relev issuer discuss herein within author
analyst coverag univers ii part author analyst compens directli indirectli relat
specif recommend view express author analyst research
analyst employ outsid us regist research analyst finra analyst may associ person
canaccord genuiti llc therefor may subject finra rule nyse rule restrict commun
subject compani public appear trade secur held research analyst account
individu identifi sector coverag cover subject compani industri identifi jurisdict author
analyst report
date time first dissemin may et
date time product may et
pt match purchas price abax agre merger agreement impli ev/rev multipl
abax revenu abax prior year ep
pt use multipl revenu estim discount back year discount rate
pt use multipl adj ep y/i
risk achiev target price valuat
competit competit human veterinari diagnost market intens may intensifi though abaxi primari vet
marketplac current duopoli vet market abaxi compet industri titan seen rise
competit activ third largest player
variabl order pattern guidanc abaxi busi lumpi depend pace distributor order
make forecast quarter difficult result manag chosen provid guidanc result lack
visibl may result wide rang consensu estim
econom sensit abax revenu function sell anim health clinic predominantli bill pet owner
self-pay basi macroeconomic activ employ wage home valu result chang pet owner budget
anim health industri sticki econom recess would neg impact abax busi
last sever year achiev meaning multipl expans trade rel similar multipl
competitor abax trade premium multipl slowdown us economi
anim health util could slow revenu margin growth particularli given industri almost self-pay small
penetr health plan insur competit abax particularli abax idexx replic strategi
mirror chang distributor relationship contribut risk associ
busi oversea execut build ou busi consum price time new product launch
abil innov keep industri leader fewer capit resourc smaller compani risk rel competitor
oper refer lab offer product certain new product categori exampl sdma test
thu present posit cross-sel across product well industry-lead abil maintain
expand us market share strong competitor leverag larger budget invest signific new product launch
valuat trade continu trade meaning premium us healthcar compani compani
 result guarante continu trade higher even abl exceed guidanc
util anim health underli demand anim health patient offic visit strong steadi year idexx
could see pressur event underli anim health util reach peak level turn could impli difficult
hold unchang target price may
diagnost tool
econom pressur unemploy rate tick lower rel level seen great recess variou
macroeconom headwind could reduc demand diagnost pet servic econom weak could caus pet owner skip
defer visit vet hospit could affect owner willing approv certain diagnost test compli treatment plan
even continu own pet
larg intern exposur deriv revenu outsid north america intern growth rate
commonli exceed unit state guarante occur futur believ intern growth
volatil growth rate us addit currenc fluctuat intern sale may continu
advers impact revenu earn
competit competit veterinari diagnost market high time intens although vet diagnost market
less duopoli compani compet commerci clinic lab hospit clinic lab manufactur multi-test blood
analyz on-sit test system expect competit abaxi particular remain rel high
regulatori risk product subject usda foreign regulatori agenc respect product
approv manufactur market promot label record keep test qualiti storag product dispos howev
regulatori risk lower human medic compani
distribut rate
global stock rate
total includ stock review
buy stock expect gener risk-adjust return next month
hold stock expect gener risk-adjust return next month
sell stock expect gener neg risk-adjust return next month
rate canaccord genuiti provid research coverag relev issuer
risk-adjust return refer expect return relat amount risk associ design invest
specul stock bear significantli higher risk typic valu normal fundament criteria invest
stock may result materi loss
recommend histori date global stock rate tabl
list recommend issuer coverag dissemin preced period
may obtain follow websit provid hyperlink report read electron http //disclosures-
requir company-specif disclosur date public
